What is Galaxy Diagnostics?
Galaxy Diagnostics is at the forefront of identifying elusive pathogens, including Bartonella, Babesia, and Borrelia, which frequently evade standard immune responses and lead to diagnostic challenges. The company employs sophisticated testing methodologies that integrate both direct and indirect detection techniques. These innovative solutions equip healthcare providers with critical, actionable data essential for refining patient care strategies. Committed to scientific integrity, Galaxy Diagnostics ensures its diagnostic tools are validated through peer-reviewed research and demonstrate clear clinical relevance, serving medical professionals nationwide.
How much funding has Galaxy Diagnostics raised?
Galaxy Diagnostics has raised a total of $3.7M across 3 funding rounds:
Private Equity
$550K
Debt
$119K
Private Equity
$3M
Private Equity (2014): $550K, investors not publicly disclosed
Debt (2021): $119K led by PPP
Private Equity (2026): $3M, investors not publicly disclosed
Key Investors in Galaxy Diagnostics
PPP
Public-Private Partnership
What's next for Galaxy Diagnostics?
The substantial enterprise-level funding Galaxy Diagnostics has garnered signals a strong market validation and provides the necessary resources for scaling its operations and further research into complex diagnostic challenges. This strategic capital infusion is expected to accelerate the development of next-generation testing platforms and expand the company's reach within the healthcare sector. The focus will likely remain on enhancing diagnostic accuracy for stealth pathogens, thereby improving patient outcomes and solidifying its position as a leader in specialized diagnostic solutions.
See full Galaxy Diagnostics company page
